None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: -patients who provide valid informed consent to RFA prior to the study procedure -Patients with the final diagnosis of papillary thyroid cancer [PTC] (Bethesda category VI) or suspicious for PTC (Bethesda category V) who meet the following inclusion criteria - Age >19 - Nodule size: >=5mm and <=1.0cm - No evidence of pathologically confirmed or clinically suspected lymph node or distant metastasis - PTC subtypes other than those with poor prognosis (tall cell, diffuse sclerosing, columnar cell, solid variant) - No radiologic evidence of direct invasion to adjacent organs including the trachea, esophagus, perithyroidal nerves, vessels, or muscles - Nodules for which complete ablation is deemed to be technically feasible on US evaluation - Patients who give informed consent to undergo RFA instead of active surveillance or immediate surgery and serial follow-up US examination on a regular basis - No bleeding tendency on blood tests (complete blood count [CBC], prothrombin time [PT], activated Partial Thromboplastin Time [aPTT])
Exclusion criteria
Exclusion criteria: - who cannot be routinely followed up according to the study schedule - Those who have difficulty understanding due to various physical conditions such as illiteracy and poor eyesight - Age under 19 - When multiple thyroid cancer is suspected - Suspected metastasis of thyroid cancer, extrathyroidal invasion, bronchial invasion, or vocal cord nerve paralysis - Pregnant - Patients using artificial pacemakers - Patients with bleeding tendencies or unable to stop taking antithrombotic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of tumor size and volume | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of lymph node metastasis or distant metastasis, change in quality of life, Delayed surgery | — |
Countries
Korea, Republic of
Contacts
Asan Medical Center